iShares Biotechnology ETF
874 hedge funds and large institutions have $4.59B invested in iShares Biotechnology ETF in 2024 Q4 according to their latest regulatory filings, with 117 funds opening new positions, 208 increasing their positions, 325 reducing their positions, and 114 closing their positions.
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
3.42% more ownership
Funds ownership: 67.57% → 71% (+3.4%)
3% more first-time investments, than exits
New positions opened: 117 | Existing positions closed: 114
2% less funds holding
Funds holding: 893 → 874 (-19)
11% less capital invested
Capital invested by funds: $5.16B → $4.59B (-$566M)
36% less repeat investments, than reductions
Existing positions increased: 208 | Existing positions reduced: 325
49% less call options, than puts
Call options by funds: $424M | Put options by funds: $829M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$73M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$47.4M |
| 3 |
Barclays
London,
United Kingdom
|
+$45.2M |
| 4 |
Morgan Stanley
New York
|
+$44.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$31.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$143M |
| 2 |
Goldman Sachs
New York
|
-$71.8M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$37.4M |
| 4 |
JP Morgan Chase
New York
|
-$36.1M |
| 5 |
LPL Financial
San Diego,
California
|
-$27.1M |
IBB Hedge Fund Activity: Q4 2024 in Review
874 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2024, worth a combined $4.59B — down 11% from $5.16B a quarter earlier.
Buyers outnumbered sellers: 117 funds opened new IBB positions and 114 closed out — a net gain of 3 holders — while 208 added to existing stakes and 325 trimmed.
The largest buyer was Jane Street, adding an estimated $73M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $143M.
- 874 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2024, down from 893 in Q3 2024.
- Funds reported $4.59B of iShares Biotechnology ETF stock for Q4 2024, down 11% quarter-over-quarter.
- 117 funds opened new iShares Biotechnology ETF positions in Q4 2024 and 114 closed out, a net change of +3 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2024 was Jane Street, an estimated $73M added.
- The largest iShares Biotechnology ETF seller in Q4 2024 was BNP Paribas Financial Markets, an estimated $143M sold.
Based on aggregated 13F filings for Q4 2024.